NASDAQ: NVAX - Novavax, Inc.

Yield per half year: +183.88%
Sector: Healthcare

Download the report: word Word , pdf PDF

1. Summary

Advantages

  • Positive review Current debt level 15.12% is below 100% and has decreased over 5 years from 164.04%.
  • Positive review The company's current efficiency (ROE=80.69%) is higher than the sector average (ROE=11.82%)

Disadvantages

  • Negative review Price (15.5 $) is higher than fair price (13.85 $)
  • Negative review Dividends (0%) are below the sector average (1.871%).
  • Negative review The stock's return over the last year (108.61%) is lower than the sector average (4432388531.56%).

2. Share price and performance

2.1. Share price

2.2. News

2.3. Market efficiency

Novavax, Inc. Healthcare Index
7 days 4.8% 0% -4.9%
90 days 193% 4040409587.9% 2.7%
1 year 108.6% 4432388531.6% 24.5%

Negative review NVAX vs Sector: Novavax, Inc. has significantly underperformed the "Healthcare" sector by -4432388422.94% over the past year.

Positive review NVAX vs Market: Novavax, Inc. has outperformed the market by 84.11% over the past year.

Neutral review Slightly volatile price: NVAX is more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical deviations of about +/- 5-15% per week.

Long period: NVAX with weekly volatility of 2.09% over the past year.

3. Summary of the report

3.1. General

P/E: 0
P/S: 0.5173

3.2. Revenue

EPS -5.41
ROE 80.69%
ROA -26.5%
ROIC -156.65%
Ebitda margin -38%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Negative review Above fair price: The current price (15.5 $) is higher than the fair price (13.85 $).

Negative review Price is higher than fair: The current price (15.5 $) is 10.6% higher than the fair price.

4.2. P/E

Positive review P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (42.58).

Positive review P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (54.92).

4.2.1 P/E Similar companies

4.3. P/BV

Positive review P/BV vs Sector: The company's P/BV (-0.7098) is lower than that of the sector as a whole (4.69).

Positive review P/BV vs Market: The company's P/BV (-0.7098) is lower than that of the market as a whole (2.35).

4.4. P/S

Positive review P/S vs Sector: The company's P/S indicator (0.5173) is lower than that of the sector as a whole (4.77).

Positive review P/S vs Market: The company's P/S indicator (0.5173) is lower than that of the market as a whole (9.99).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

Positive review EV/Ebitda vs Sector: The company's EV/Ebitda (-0.5634) is lower than that of the sector as a whole (16.28).

Positive review EV/Ebitda vs Market: The company's EV/Ebitda (-0.5634) is lower than that of the market as a whole (22.79).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Ebitda

Positive review Yield Trend: Rising and has grown by 80.11% over the last 5 years.

Negative review Earnings Slowdown: The last year's return (0%) is below the 5-year average return (80.11%).

Negative review Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (1404.06%).

5.4. ROE

Positive review ROE vs Sector: The company's ROE (80.69%) is higher than that of the sector as a whole (11.82%).

Positive review ROE vs Market: The company's ROE (80.69%) is higher than that of the market as a whole (31.82%).

5.5. ROA

Negative review ROA vs Sector: The company's ROA (-26.5%) is lower than that of the sector as a whole (6.99%).

Negative review ROA vs Market: The company's ROA (-26.5%) is lower than that of the market as a whole (6.37%).

5.6. ROIC

Negative review ROIC vs Sector: The company's ROIC (-156.65%) is lower than that of the sector as a whole (13.31%).

Negative review ROIC vs Market: The company's ROIC (-156.65%) is lower than that of the market as a whole (10.68%).

6. Finance

6.1. Assets and debt

Positive review Debt level: (15.12%) is quite low in relation to assets.

Positive review Debt reduction: over 5 years, the debt has decreased from 164.04% to 15.12%.

Negative review Excess of debt: The debt is not covered by net income, percentage -51.48%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Negative review Low yield: The dividend yield of the company 0% is below the average for the sector '1.871%.

7.2. Stability and increase in payments

Negative review Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Negative review Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Negative review Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Negative review Insider Selling More insider purchases by 480.12% over the last 3 months.

8.2. Latest transactions

Transaction date Insider Type Price Volume Quantity
14.05.2024 Dubovsky Filip
President, R&D
Sale 13.9 657 637 47312
14.05.2024 Dubovsky Filip
President, R&D
Buy 6.97 136 974 19652